Novo Nordisk stock forecast: 2026 sales guidance cut

Novo Nordisk (NVO) trades near recent lows after February 2026 guidance for -5% to -13% sales growth; FDA warning letters on 3 March briefly supported shares. Past performance is not a reliable indicator of future results. Explore third-party NVO price targets and technical analysis.

By Dan Mitchell7 hours ago

Photo: Shutterstock

Novo Nordisk (NVO) is trading at $39.05 in early European trading on 6 March 2026, with an intraday range of $38.32–$39.36 as of 9:47am UTC. The stock sits near its recent 52-week low of $36.72, recorded on 3 March 2026, having declined sharply from above $48 in mid-February, reflecting sustained selling pressure following the company’s full-year results. Past performance is not a reliable indicator of future results.

Sentiment has been weighed down by Novo Nordisk’s February 2026 guidance, in which the company forecast 2026 adjusted sales growth of -5% to -13% at constant exchange rates, significantly below prior analyst expectations of a roughly 2% decline (The Pharma Letter, 4 February 2026). The company cited intensifying competition in the GLP-1 obesity market from rival Eli Lilly and pricing headwinds tied to US drug-pricing agreements under the US administration (CNBC, 24 February 2026) . A partial offset emerged on 3 March 2026, when the FDA issued warning letters to 30 telehealth companies over misleading claims relating to GLP-1 drugs, prompting NVO shares to rise over 3% in that session (FDA, 3 March 2026); meanwhile, broader pharma sector activity has been supported by a pickup in M&A and pipeline partnerships, with Novo Nordisk itself announcing a multi-billion-DKK collaboration with Vivtex for next-generation oral biologic delivery (Pharmaceutical Technology, 26 February 2026).

Novo Nordisk stock forecast 2026–2030: Third-party price targets

As of 6 March 2026, third-party Novo Nordisk stock predictions have been heavily revised since late January 2026, with the re-rating accelerating in late February following the CagriSema Phase 3 trial setback; 12-month consensus targets now span roughly $40–$74, compared to $80 and above in mid-2025. The following targets summarise recent broker and consensus assessments.

Deutsche Bank (downgrade to Hold, 275 DKK target)

Deutsche Bank analyst Emmanuel Papadakis downgraded Novo Nordisk to Hold from Buy, cutting his price target to 275 DKK from 400 DKK, a reduction of 31%. Papadakis attributed the move to CagriSema’s failure to demonstrate non-inferiority versus Eli Lilly’s tirzepatide in the REDEFINE-4 Phase 3 trial, with the bank now modelling 2026–2030 estimates at 5%–21% below Bloomberg consensus (MarketWatch, 23 February 2026).

Kepler Capital Markets (downgrade to Hold)

Kepler Capital Markets downgraded Novo Nordisk to Hold from Buy, contributing to a session in which NVO shares touched $37.65 on volume roughly 104% above the daily average. The downgrade followed the CagriSema trial miss and came alongside the company’s weaker-than-expected 2026 sales guidance issued earlier that month, as Kepler flagged reduced confidence in near-term pipeline catalysts (MarketBeat, 25 February 2026).

Goldman Sachs (reaffirmed Neutral, $41 target)

Goldman Sachs reaffirmed a Neutral rating on NVO and cut its 12-month price target to $41 from $63, a reduction of roughly 35%, with the stock trading near its 52-week low of $37.31 at the time. The bank cited mounting GLP-1 pricing headwinds and a deteriorating near-term revenue trajectory, while noting NVO’s Q4 2025 EPS of $1.01 had beaten the $0.90 consensus estimate (MarketBeat, 2 March 2026).

Morgan Stanley (upgrade to Equal-weight, $40 target)

Morgan Stanley upgraded Novo Nordisk to Equal-weight from Underweight, assigning a $40 price target and prompting a 5.1% intraday rally to $38.53 on volume of approximately 26.4 million shares. The firm said the recent sell-off has better priced in mid-term risks, including concentration around semaglutide and the planned halving of Wegovy’s US list price in 2027, while noting the stock’s price-to-earnings ratio had compressed to approximately 11x 2026 estimates (MarketBeat, 4 March 2026).

Public.com (consensus overview, $57.92 average target)

Public.com aggregates analyst NVO stock forecasts, reporting a consensus 12-month price target of $57.92, with a Buy consensus rating derived from six analysts; the breakdown shows 33% Strong Buy, 17% Buy, 33% Hold, and 17% Sell. The wide dispersion in individual targets reflects the unresolved debate between those who see current valuations as pricing in sufficient downside and those who flag continued pipeline, pricing, and competitive risks that may not yet be fully reflected (Public.com, 4 March 2026).

Takeaway: recent 12-month Novo Nordisk stock predictions converge in the $40–$42 range at the lower end from Goldman Sachs and Morgan Stanley, while broader consensus aggregates from Public.com sit closer to $58; the common thread across all late-February and early-March 2026 revisions is the dual weight of the CagriSema trial miss and the company’s own below-consensus 2026 guidance.

Predictions and third-party forecasts are inherently uncertain, as they cannot fully account for unexpected market developments. Past performance is not a reliable indicator of future results.

NVO stock price: Technical overview

The NVO stock price trades at $39.05 as of 9:47am UTC on 6 March 2026, sitting just above the 10-day simple moving average (SMA) near $39 but well beneath the broader moving average stack, where the 20/50/100/200-day SMAs line up at approximately $44 / $51 / $51 / $57 respectively. Every SMA from the 10-day through the 200-day is sloping lower and points to bearish conditions, with price trading well below most key levels, reflecting a sustained downtrend across all measured timeframes.

Momentum remains under pressure: the 14-day relative strength index (RSI) reads 32.72, sitting in the lower neutral band and approaching oversold territory without yet triggering a confirmed reversal signal. The average directional index (ADX) at 37.19 confirms an established trend is in force, lending weight to the prevailing directional move.

To the upside, the classic R1 pivot at $52.06 is the first meaningful overhead reference; a daily close above that level could bring R2 near $66.68 into view for some technicians. The 20-day SMA near $44 acts as a closer interim ceiling, given price has traded beneath it throughout the current leg lower.

On the downside, the classic pivot point (P) at $44.69 now acts as resistance rather than support from below. Initial support rests at S1 near $30.07; a sustained move under current levels toward that zone would open a deeper retracement, while the S2 area near $22.70 represents the next classical reference on an extended decline (TradingView, 6 March 2026).

This is technical analysis for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any instrument.

Novo Nordisk share price history (2024–2026)

NVO’s stock price traded above $138 in early March 2024, near the top of a multi-year rally driven by surging demand for its GLP-1 weight-loss drug Wegovy and diabetes treatment Ozempic. The stock held broadly in the $120–$148 range through mid-2024, reaching a two-year peak of $148.23 on 25 June 2024, before a gradual retreat began in the second half of the year.

By December 2024, NVO was still holding above $100, closing at $112.05 on 11 December 2024, but the picture changed sharply on 20 December when the stock gapped down to close at $85.17 – a single-session decline of roughly 19% – following disappointing Phase 3 trial data for CagriSema. NVO ended 2024 at $86.22, down approximately 37% from its June peak.

The sell-off deepened through early 2026. After briefly stabilising in the $83–$92 range across February and March 2025, the stock came under renewed pressure, sliding from around $90 in late February 2025 to the mid-$70s by mid-March and continuing lower through the summer. NVO touched a two-year low of $35.91 on 3 March 2026 following a wave of analyst downgrades and the company’s own below-consensus 2026 revenue guidance, before recovering slightly to trade near $39.19 on 6 March 2026 – approximately 55% below its June 2024 peak.

Past performance is not a reliable indicator of future results.

Novo Nordisk (NVO): Capital.com analyst view

Novo Nordisk’s share price has undergone a substantial re-rating over the past year, with NVO declining from above $148 in mid-2024 to trade near $39 in early March 2026, reflecting a combination of clinical setbacks, competitive pressure in the GLP-1 market, and a weaker-than-expected 2026 revenue outlook issued by the company itself. For some market participants, the scale of the sell-off may suggest the stock has priced in a significant portion of the near-term headwinds, particularly given NVO’s continued presence in diabetes and obesity care; others, however, point to the Eli Lilly competitive threat and potential US drug-pricing reforms as factors that could sustain downward pressure on earnings estimates.

The broader pharmaceutical sector backdrop adds further nuance: recent FDA enforcement actions against telehealth providers misusing GLP-1 branding could support Novo Nordisk’s branded product positioning, though pricing concessions tied to US formulary access agreements remain a structural drag that the company has itself acknowledged. How NVO navigates the tension between volume growth and price erosion is likely to remain a key point of focus for those monitoring the stock.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Past performance is not a reliable indicator of future results.

Capital.com’s client sentiment for Novo Nordisk CFDs

As of 6 March 2026, Capital.com client positioning in Novo Nordisk CFDs shows 97.7% buyers vs 2.3% sellers, putting buyers ahead by 95.4 percentage points and placing sentiment firmly in heavy-buy, one-sided-toward-longs territory. This snapshot reflects open positions on Capital.com and can change. It does not predict future price movements.

Summary – Novo Nordisk 2026

NVO trades at $39.05 as of 9:47am UTC on 6 March 2026, down roughly 55% from its two-year peak of $148.23 recorded in June 2024.
All moving averages from the 10-day through the 200-day are aligned bearishly above price; the 14-day RSI sits at 32.72, approaching oversold territory amid an established downtrend confirmed by an ADX of 37.19.
The primary price driver has been Novo Nordisk’s own February 2026 guidance, projecting 2026 sales to decline 5%–13% at constant exchange rates, well below prior analyst expectations.
Competitive pressure from Eli Lilly’s tirzepatide and US drug-pricing concessions under the US administration continue to weigh on NVO’s earnings outlook and analyst price targets.

Past performance is not a reliable indicator of future results.

FAQ

Who owns the most Novo Nordisk stock?

Novo Nordisk uses a dual-class share structure. Novo Holdings A/S holds the unlisted A shares, which carry enhanced voting rights, and Novo Holdings is wholly owned by the Novo Nordisk Foundation. This structure allows the Foundation, through Novo Holdings, to maintain controlling influence even though most publicly traded shares are B shares. Institutional and retail ownership of the listed shares changes over time as investors buy and sell.

What is the 5 year Novo Nordisk share price forecast?

You will often see 12-month analyst price targets, but reliable five-year NVO stock forecasts are uncommon and can vary widely because assumptions about competition, pricing, and clinical outcomes can change. A practical way to think about a five-year horizon is to focus on drivers (pipeline progress, demand trends, pricing agreements, and market share) and risks (trial setbacks, regulation, and competitive pressure), rather than a single number.

Is Novo Nordisk a good stock to buy?

Whether Novo Nordisk is 'good' depends on your objectives, time horizon, and risk tolerance. The recent re-rating highlighted how quickly expectations can change after guidance updates, competitive developments in GLP-1 therapies, and trial news. Some investors focus on the company’s scale in diabetes and obesity care, while others focus on pricing pressure and pipeline uncertainty. This article provides information, not a recommendation, and you should consider independent research before making decisions.

Could Novo Nordisk stock go up or down?

Yes. Novo Nordisk shares can move up or down in response to earnings results, updated guidance, trial data, regulatory actions, and competitor announcements. Technical factors, such as trend strength and momentum indicators, can also influence how traders interpret price action, especially around widely watched levels like moving averages or pivots. Because markets price in expectations, news that changes assumptions about revenue, margins, or long-term growth can shift sentiment quickly in either direction.

Should I invest in Novo Nordisk stock?

I can’t tell you whether you should invest, as that would be financial advice. If you’re evaluating Novo Nordisk, you can frame the decision around your risk capacity, diversification, and whether you understand the main uncertainties highlighted in the article, including competition in GLP-1 treatments and potential pricing headwinds. Many investors also review multiple sources, scenario-test assumptions, and consider speaking with a regulated adviser if they need personalised guidance.

Can I trade Novo Nordisk (NVO) CFDs on Capital.com?

Yes, you can trade Novo Nordisk CFDs on Capital.com. Trading share CFDs lets you speculate on price movements without owning the underlying asset and to take long or short positions. However, contracts for difference (CFDs) are traded on margin, and leverage amplifies both profits and losses. You should ensure you understand how CFD trading works, assess your risk tolerance, and recognise that losses can occur quickly.